Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer

Recruiting now

Conditions studied: Advanced Metastatic Breast Cancer

In brief

A Pilot study on circulating tumor DNA (ctDNA) in advanced/metastatic breast cancer with low levels of HER2 expression (HER2 low)

Key facts

Study ID

NCT06706557

Run by

European Institute of Oncology

People needed

30

Starts

2024-01-11

Expected to finish

2030-12-31

Last updated by the study team

2026-03-24

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Participants diagnosed with HER2-low breast cancer, defined as IHC score 1+ or 2+ and not amplified at in situ hybridization (ISH) test as confirmed by local laboratory testing.
• Participants should be at advanced or metastatic setting prior to treatment.
• Written informed consent (Accordo di Partecipazione alla Ricerca Scientifica) and specific informed consent to the study must be signed and dated by the patient and the doctor prior to inclusion.
• Patients must be accessible for follow-up.

Where it is running

• European Institute of Oncology — Milan, MI, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.